Cargando…
Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure
Bucindolol is a non-selective β-adrenergic receptor blocker with α-1 blocker properties and mild intrinsic sympatholytic activity. The Beta-Blocker Evaluation of Survival Trial (BEST), which is the largest clinical trial of bucindolol in patients with heart failure, was terminated prematurely and fa...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140276/ https://www.ncbi.nlm.nih.gov/pubmed/21792345 http://dx.doi.org/10.4137/CMC.S4309 |